指南与共识生殖医学妇科

2023年国际循证指南:多囊卵巢综合征评估与管理建议

Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome†.
指南 / 共识 · Hum Reprod · 2023-01-01

2023年国际循证指南更新基于现有最佳证据、临床专业知识和患者偏好,针对多囊卵巢综合征(PCOS)的评估与管理提出254条推荐和实践要点,旨在促进一致、循证的照护并改善患者体验和健康结局。证据总体仍为低至中等质量。

要点

  • 指南包含77条循证推荐、54条共识推荐和123条实践要点。
  • 关键更新包括细化个体化诊断标准、简化诊断流程,并仅在成人中将抗苗勒管激素(AMH)水平作为超声的替代方法。
  • 强调识别PCOS更广泛的特征,包括代谢危险因素、心血管疾病、睡眠呼吸暂停、心理特征高患病率及妊娠期不良结局高风险。

核心结论

  • 2023年国际PCOS指南为临床医生和患者提供了基于最佳可用证据、多学科专家意见和患者偏好的明确最佳实践建议。

研究设计与样本

  • 指南更新重新召集了2018年网络,涉及39个专业和患者组织、覆盖71个国家,在12个月内召开20次会议和5次面对面论坛,处理58个优先临床问题,包括52项系统综述和3项叙述性综述。
  • 遵循AGREEII合规流程,应用GRADE框架评估证据质量、可行性、可接受性、成本、实施和推荐强度,并全程考虑多样性和包容性。
  • 指南经五个指南制定小组共识批准,根据国际反馈和同行评审修改,独立方法学审查,并由澳大利亚政府国家健康与医学研究委员会(NHMRC)批准。

主要发现

  • 证据技术报告和分析约6000页,支持77条循证推荐和54条共识推荐,以及123条实践要点。
  • 诊断标准进一步细化,简化诊断算法,并仅在成人中纳入抗苗勒管激素(AMH)水平作为超声的替代方法。
  • 加强了对PCOS更广泛特征的认识,包括代谢危险因素、心血管疾病、睡眠呼吸暂停、心理特征高患病率以及妊娠期不良结局高风险状态。
  • 强调疾病负担的多样性和未被充分认识,需要加强医疗专业人员教育、循证患者信息、改进照护模式和共享决策。
  • 维持对健康生活方式、情绪健康和生活质量的重视,并关注和考虑体重污名。

关键数值与推荐

  • 指南共包含254条推荐和实践要点,其中77条循证推荐、54条共识推荐和123条实践要点。
  • 仅在成人中,抗苗勒管激素(AMH)水平可作为超声的替代方法用于诊断。
  • 推荐加强识别PCOS的代谢危险因素、心血管疾病、睡眠呼吸暂停、心理特征和妊娠期不良结局高风险。

局限性

  • 总体推荐得到加强,证据有所改善,但仍普遍为低至中等质量。
  • 在这一被忽视但常见的疾病中,现在需要显著更多的研究。
  • 考虑了并承认区域卫生系统的差异,并提供了指南和翻译资源适应的进一步流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? SUMMARY ANSWER: International evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS. WHAT IS KNOWN ALREADY: The 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from six continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low to low quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, evidence quality was low and evidence-practice gaps persist. STUDY DESIGN, SIZE, DURATION: The 2023 International Evidence-based Guideline update reengaged the 2018 network across professional societies and consumer organizations, with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength and diversity and inclusion were considered throughout. PARTICIPANTS/MATERIALS, SETTING, METHODS: This summary should be read in conjunction with the full Guideline for detailed participants and methods. Governance included a six-continent international advisory and management committee, five guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health and other experts, alongside consumers, project management, evidence synthesis, statisticians and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and five face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across five guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council (NHMRC). MAIN RESULTS AND THE ROLE OF CHANCE: The evidence in the assessment and management of PCOS has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report and analyses (∼6000 pages) underpins 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include: i) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti-Müllerian hormone (AMH) levels as an alternative to ultrasound in adults only; ii) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; iii) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care and shared decision making to improve patient experience, alongside greater research; iv) maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and v) emphasizing evidence-based medical therapy and cheaper and safer fertility management. LIMITATIONS, REASONS FOR CAUTION: Overall, recommendations are strengthened and evidence is improved, but remains generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided. WIDER IMPLICATIONS OF THE FINDINGS: The 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the Guideline with an integrated evaluation program. STUDY FUNDING/COMPETING INTEREST(S): This effort was primarily funded by the Australian Government via the National Health Medical Research Council (NHMRC) (APP1171592), supported by a partnership with American Society for Reproductive Medicine, Endocrine Society, European Society for Human Reproduction and Embryology, and European Society for Endocrinology. The Commonwealth Government of Australia also supported Guideline translation through the Medical Research Future Fund (MRFCRI000266). HJT and AM are funded by NHMRC fellowships. JT is funded by a Royal Australasian College of Physicians (RACP) fellowship. Guideline development group members were volunteers. Travel expenses were covered by the partnering organizations. Disclosures of interest were strictly managed according to NHMRC policy and are available with the full guideline, technical evidence report, peer review and responses (www.monash.edu/medicine/mchri/pcos). Of named authors HJT, CTT, AD, LM, LR, JBoyle, AM have no conflicts of interest to declare. JL declares grant from Ferring and Merck; consulting fees from Ferring and Titus Health Care; speaker's fees from Ferring; unpaid consultancy for Ferring, Roche Diagnostics and Ansh Labs; and sits on advisory boards for Ferring, Roche Diagnostics, Ansh Labs, and Gedeon Richter. TP declares a grant from Roche; consulting fees from Gedeon Richter and Organon; speaker's fees from Gedeon Richter and Exeltis; travel support from Gedeon Richter and Exeltis; unpaid consultancy for Roche Diagnostics; and sits on advisory boards for Roche Diagnostics. MC declares travels support from Merck; and sits on an advisory board for Merck. JBoivin declares grants from Merck Serono Ltd.; consulting fees from Ferring B.V; speaker's fees from Ferring Arzneimittell GmbH; travel support from Organon; and sits on an advisory board for the Office of Health Economics. RJN has received speaker's fees from Merck and sits on an advisory board for Ferring. AJoham has received speaker's fees from Novo Nordisk and Boehringer Ingelheim. The guideline was peer reviewed by special interest groups across our 39 partner and collaborating organizations, was independently methodologically assessed against AGREEII criteria and was approved by all members of the guideline development groups and by the NHMRC.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome†. Hum Reprod. 2023. PMID: 37580037. doi:10.1093/humrep/dead156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。